MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Dr. DeshBandhu Gupta’s Lupin- Aplace where pharmaceutical-based innovation meets a milestone

The Silicon Review
September, 2019

thesiliconreview-dr-deshbandhu-gupta-founder-lupin-2019.jpg

The pharmaceutical industry is setting up new trends in the field of pharmacy and Biological sciences. The main of the firm is to discover and develop new drugs and to bring them into the market. Pharmaceutical industry aims to bring in new discoveries such as vaccines, pills and other generic medicines. It mainly deals with medications and medical devices. They do hold patenting rights on certain medications; they also perform efficient drug testing, drug safety tests, and marketing of the newly formulated drugs.

The pharmaceutical industry plays a vital role in the field of Life Sciences. One's such pioneer pharmaceutical industry which is leading with an example is Lupin. It was founded in the year 1968 by Dr. DeshBandhu Gupta. The main purpose of starting the firm was to fight life-threatening, infectious diseases with affordable and high-quality drugs of the highest social priority, inimitable commitment, and passion.

The organization is one of the fastest-growing Generic pharmaceutical companies around the world.The name ‘Lupin’ was inspired by the flower Lupin which is known to nourish the soil it grows in and which is also tolerant to infertile soils and is capable of changing the barren and poor climatic condition.

Products Manufactured by the company

Lupin is recognized as one of the world's largest manufacturers of Tuberculosis drugs. The firm has significant market share across multiple therapy areas such as Cardiovascular (pills and statins), Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Research at Lupin

The world of life sciences is converging like never before and the convergence of pharmaceutical, biotechnology, and medical technology would improve outcomes that could dramatically alter drug development and drug targeting. At Lupin, they use advanced technologies, scientific breakthroughs, and partnerships that enable the firm to advance research and development towards building a diversified portfolio and gain a leadership position in important new product introductions. The company’s Research & Development helps in building a solid foundation to become a Complex Generics, Biosimilars, and Specialty frontrunner.

Global formulation

Lupin has a deep-rooted commitment to drive cutting-edge research and build world-class capabilities in manufacturing, supply chain, and commercialization to meet the pressing needs in medical care. The firm believes in commitment to embrace superior quality, unyielding integrity and strict compliance across business operations.

The firm has established a well-balanced global business in both advanced and developing markets. Our investments are well-calibrated towards developing meaningful Generic products, Complex Generics and Specialty. Our inherent strength of entrepreneurship, agility, and innovation are the key differentiators thatlead us towards the next growth orbit. The firm has its manufacturing units spread across India, the US, Japan, Mexico, and Brazil.

Corporate Responsibility

The firm has started its own foundation named The Lupin Foundation which helps to develop the rural sectors. Some of them include;

Economic

The firm is creating more employment opportunities particularly for unemployed youth and women, and also strengthening primary occupations like agriculture and animal husbandry through increased output & value addition, and providing secondary occupations such as cottage industry, handicrafts, and service sector through quality enhancement and wider market acceptability

Social

The firm is focusing to develop proper social, cultural, scientific and spiritual attitude amidst rural community and instill in villagers an urge and keenness to work for their own development

Infrastructure

To create basic infrastructure facilities for the community such as Provision for drinking water, Building internal roads, Basic sanitation, Formal education, Community centers, Electrification

Scale-up Strategy

Lupin's foundation closely works with central and state governments and their departments as well as with international organizations to achieve its objectives. The convergence and collaboration are an integral part of its strategy.

Milestones achieved

Filed a new drug application for EtanerceptBiosimilarIn Japan, acquiredSymbiomix Therapeutics, LLC In New Jersey, expandedIts branded play with exclusive US Rights to Alinia for oral suspensions, entered the NIFTY 50 Index, commissioned Injectable facility at Nagpur and has achieved several other feats.

The staunch behind the domicile of Lupin

Dr. DeshBandhu Gupta, the Founder and Former chairperson of Lupin is a pioneer in the field of Chemistry. The firm was his dream, journey,and belief. He holds a postgraduate degree in Chemistry from Bombay University. He started Lupin in the year 1968, with his wife, Mrs. Manju Gupta and has served as the first investor with an investment of INR 5,000. To him, Lupin was a weapon to fight life-threatening diseases that plagued his nation. His personality has encouraged learning from the experiences and never rest on laurels. He has inspired the team to move ahead, set high targets and meet one’s goals through an unyielding commitment to compliance and integrity.

"Commit to strengthening yourself such that the universe bends to your will."

YOU MAY ALSO LIKE

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...

Business Travelers to Stay at Singapore’s Changi Airport Bubble

Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...

Countries in Asia-Pacific are marching towards ‘green recovery’ amidst Covid-19 crisis

2020 has been an unforgettable year for many of us. The ongoing Covid crisis has reminded people that it is very important to have an uninterrupted an...

Department of Telecommunication to announce the new schedule for 5G trials

Department of Telecommunications (DoT) is all set to announce the new schedule for 5G trials. The Dot made this decision after being pulled by the par...

RECOMMENDED